scholarly journals PhoneMD: Learning to Diagnose Parkinson’s Disease from Smartphone Data

Author(s):  
Patrick Schwab ◽  
Walter Karlen

Parkinson’s disease is a neurodegenerative disease that can affect a person’s movement, speech, dexterity, and cognition. Clinicians primarily diagnose Parkinson’s disease by performing a clinical assessment of symptoms. However, misdiagnoses are common. One factor that contributes to misdiagnoses is that the symptoms of Parkinson’s disease may not be prominent at the time the clinical assessment is performed. Here, we present a machine-learning approach towards distinguishing between people with and without Parkinson’s disease using long-term data from smartphone-based walking, voice, tapping and memory tests. We demonstrate that our attentive deep-learning models achieve significant improvements in predictive performance over strong baselines (area under the receiver operating characteristic curve = 0.85) in data from a cohort of 1853 participants. We also show that our models identify meaningful features in the input data. Our results confirm that smartphone data collected over extended periods of time could in the future potentially be used as a digital biomarker for the diagnosis of Parkinson’s disease.

Neuroscience ◽  
2020 ◽  
Vol 436 ◽  
pp. 170-183 ◽  
Author(s):  
Zhi-yao Tian ◽  
Long Qian ◽  
Lei Fang ◽  
Xue-hua Peng ◽  
Xiao-hu Zhu ◽  
...  

2021 ◽  
Author(s):  
Adolfo M. García ◽  
Tomás Arias‐Vergara ◽  
Juan Vasquez‐Correa ◽  
Elmar Nöth ◽  
Maria Schuster ◽  
...  

2013 ◽  
Vol 58 (3) ◽  
pp. 195-202 ◽  
Author(s):  
Rubén Armañanzas ◽  
Concha Bielza ◽  
Kallol Ray Chaudhuri ◽  
Pablo Martinez-Martin ◽  
Pedro Larrañaga

Author(s):  
Haithem Chtioui ◽  
Samira M Sadowski ◽  
Bettina Winzeler ◽  
Oliver Tschopp ◽  
Eric Grouzmann ◽  
...  

Background Levodopa (L-DOPA) provided to patients with Parkinson’s disease causes an increase in dopamine and methoxytyramine blood concentration which may lead to erroneous diagnosis of dopamine-producing tumours based on a plasma fractionated metanephrines and methoxytyramine assay. Considering that oral L-DOPA is mainly transformed in the gut wall into dopamine and methoxytyramine, we hypothesize that patients treated with L-DOPA produce predominantly sulphated methoxytyramine, whereas dopamine-producing tumours, devoid of sulfotransferase, will secrete free methoxytyramine. These metabolic differences may allow for discrimination between the two groups of patients through methoxytyramine plasma concentration. Methods We retrospectively investigated a cohort of 16 patients with a dopamine-secreting pheochromocytoma or paraganglioma and 22 patients treated for Parkinson’s disease to see whether the metabolic ratio of free and sulphated methoxytyramine differs. Results Receiver operating characteristic curve analysis indicates an absolute separation between the two groups when using a cut-off of free/total methoxytyramine (sum of free and sulphated methoxytyramine) ratio of 0.0059, corresponding to a free methoxytyramine fraction of 0.59% ( P < 0.0001, AUC 1.0 indicating 100% sensitivity and specificity). Conclusion Dopamine secreted by tumours and exogenous dopamine (from Parkinson’s disease treatment) follow different metabolic pathways. We observed that free/total methoxytyramine ratio may be a useful tool in distinguishing between patients with a dopamine-secreting tumour from patients treated with L-DOPA when clinical information is incomplete or lacking.


Sign in / Sign up

Export Citation Format

Share Document